Lisofylline

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lisofylline
Accession Number
DB12406
Type
Small Molecule
Groups
Investigational
Description

Lisofylline has been investigated for the treatment of Type 1 Diabetes Mellitus.

Structure
Thumb
Synonyms
Not Available
External IDs
CT 1501R
Categories
UNII
L1F2Q2X956
CAS number
100324-81-0
Weight
Average: 280.328
Monoisotopic: 280.15354052
Chemical Formula
C13H20N4O3
InChI Key
NSMXQKNUPPXBRG-SECBINFHSA-N
InChI
InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m1/s1
IUPAC Name
1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
SMILES
C[C@@H](O)CCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Lisofylline.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Lisofylline is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Lisofylline is combined with 5-androstenedione.Experimental, Illicit
AbciximabLisofylline may increase the anticoagulant activities of Abciximab.Approved
AcebutololLisofylline may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolLisofylline may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Lisofylline.Approved
AdenosineThe therapeutic efficacy of Adenosine can be decreased when used in combination with Lisofylline.Approved, Investigational
AlclofenacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Alendronic acid.Approved
AliskirenLisofylline may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Alminoprofen.Experimental
AlprenololLisofylline may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Lisofylline.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Amcinonide.Approved
AmilorideLisofylline may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Aminosalicylic Acid.Approved
AncrodLisofylline may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Lisofylline.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Lisofylline is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Lisofylline is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Lisofylline.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Lisofylline is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Antipyrine.Approved, Investigational
Antithrombin III humanLisofylline may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Antrafenine.Approved
ApixabanLisofylline may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Lisofylline is combined with Apocynin.Investigational
ApramycinLisofylline may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Lisofylline.Approved, Investigational
ArbekacinLisofylline may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinLisofylline may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanLisofylline may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololLisofylline may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineLisofylline may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Atamestane.Investigational
AtenololLisofylline may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Lisofylline.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Lisofylline.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Lisofylline is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lisofylline.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Lisofylline.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Lisofylline.Investigational
BecaplerminLisofylline may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BefunololLisofylline may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinLisofylline may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lisofylline.Approved
BenorilateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Lisofylline.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Lisofylline.Approved, Illicit
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Lisofylline.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Lisofylline.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Betamethasone.Approved, Vet Approved
BetaxololLisofylline may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Lisofylline.Approved, Investigational
BevantololLisofylline may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Lisofylline is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Lisofylline.Approved, Investigational
BisoprololLisofylline may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinLisofylline may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololLisofylline may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Lisofylline.Investigational
BucindololLisofylline may decrease the antihypertensive activities of Bucindolol.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Bufexamac.Approved, Experimental
BufuralolLisofylline may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Lisofylline.Approved
BupranololLisofylline may decrease the antihypertensive activities of Bupranolol.Approved
CaffeineThe metabolism of Lisofylline can be decreased when combined with Caffeine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Lisofylline.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Lisofylline.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Captopril.Approved
CarbamazepineThe serum concentration of Lisofylline can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Lisofylline is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Lisofylline.Approved
CarprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololLisofylline may decrease the antihypertensive activities of Carteolol.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Lisofylline.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Lisofylline is combined with Celecoxib.Approved, Investigational
CeliprololLisofylline may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinLisofylline may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lisofylline.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lisofylline.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Lisofylline.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Lisofylline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Cilazapril.Approved
CimetidineThe metabolism of Lisofylline can be decreased when combined with Cimetidine.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Lisofylline is combined with Cimicoxib.Investigational
CinoxacinLisofylline may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe serum concentration of Lisofylline can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Cisplatin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Lisofylline.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Lisofylline.Vet Approved
CloranololLisofylline may decrease the antihypertensive activities of Cloranolol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Lisofylline is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ColesevelamColesevelam can cause a decrease in the absorption of Lisofylline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Lisofylline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Cortisone acetate.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Lisofylline is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Lisofylline.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Lisofylline.Experimental
Dabigatran etexilateLisofylline may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinLisofylline may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidLisofylline may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanLisofylline may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Lisofylline is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Lisofylline is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Delapril.Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Lisofylline.Approved
DesipramineLisofylline may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinLisofylline may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Lisofylline.Approved, Investigational
DextranLisofylline may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinLisofylline may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Lisofylline is combined with Dibotermin alfa.Approved, Investigational
DicoumarolLisofylline may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Lisofylline.Approved, Illicit
DifenpiramideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Lisofylline is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lisofylline.Approved
DihydrostreptomycinLisofylline may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Lisofylline.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Lisofylline.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Lisofylline.Approved
DrospirenoneLisofylline may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Lisofylline is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Lisofylline.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Lisofylline.Investigational
Edetic AcidLisofylline may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanLisofylline may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Lisofylline is combined with Enalaprilat.Approved
EnoxacinLisofylline may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinLisofylline may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Lisofylline.Experimental
EpanololLisofylline may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Lisofylline.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Lisofylline.Experimental
EplerenoneLisofylline may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Lisofylline.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lisofylline.Approved
EquileninThe risk or severity of adverse effects can be increased when Lisofylline is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Equilin.Approved
EsatenololLisofylline may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololLisofylline may decrease the antihypertensive activities of Esmolol.Approved
EstradiolThe serum concentration of Lisofylline can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Lisofylline.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Lisofylline is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Lisofylline can be increased when it is combined with Ethinyl Estradiol.Approved
EthosuximideEthosuximide may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
Ethyl biscoumacetateLisofylline may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Lisofylline.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Lisofylline is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Lisofylline.Investigational, Nutraceutical
EverolimusThe metabolism of Lisofylline can be decreased when combined with Everolimus.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Lisofylline.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Lisofylline.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Lisofylline.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Lisofylline.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Feprazone.Experimental
Ferulic acidLisofylline may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lisofylline.Approved, Investigational
FingolimodLisofylline may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinLisofylline may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Lisofylline.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fludrocortisone.Approved, Investigational
FluindioneLisofylline may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineLisofylline may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Flumethasone.Approved, Vet Approved
FlunarizineFlunarizine may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Lisofylline.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Lisofylline.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluticasone furoate.Approved
FluvoxamineThe metabolism of Lisofylline can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Lisofylline.Approved, Nutraceutical, Vet Approved
FondaparinuxLisofylline may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Lisofylline.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Formestane.Approved, Investigational, Withdrawn
FramycetinLisofylline may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
G17DTThe risk or severity of adverse effects can be increased when Lisofylline is combined with G17DT.Investigational
GabapentinGabapentin may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
GabexateLisofylline may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinLisofylline may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinLisofylline may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Lisofylline.Approved, Withdrawn
GemifloxacinLisofylline may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinLisofylline may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinLisofylline may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ALisofylline may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The risk or severity of adverse effects can be increased when Lisofylline is combined with GI-5005.Investigational
GinsengThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinLisofylline may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Lisofylline is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Lisofylline is combined with HE3286.Investigational
HeparinLisofylline may increase the anticoagulant activities of Heparin.Approved, Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Lisofylline is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Higenamine.Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Human rabies virus immune globulin.Approved
HydralazineLisofylline may decrease the antihypertensive activities of Hydralazine.Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Lisofylline.Approved, Investigational
Hygromycin BLisofylline may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Lisofylline.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Lisofylline.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Lisofylline is combined with Icosapent.Approved, Nutraceutical
IdraparinuxLisofylline may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lisofylline.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lisofylline.Approved
IndenololLisofylline may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Lisofylline.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Lisofylline is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Lisofylline is combined with INGN 225.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Lisofylline.Approved, Investigational
IsepamicinLisofylline may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Lisofylline.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Lisofylline is combined with Istaroxime.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Lisofylline is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KanamycinLisofylline may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Lisofylline.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ketoprofen.Approved, Vet Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Lisofylline.Approved
LamotrigineLamotrigine may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
LandiololLisofylline may decrease the antihypertensive activities of Landiolol.Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Lisofylline.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Leflunomide.Approved, Investigational
LepirudinLisofylline may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanLisofylline may increase the anticoagulant activities of Letaxaban.Investigational
LevetiracetamLevetiracetam may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
LevobetaxololLisofylline may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololLisofylline may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinLisofylline may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LidocaineThe metabolism of Lisofylline can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Lisofylline.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Lisinopril.Approved, Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Lisofylline.Experimental
LomefloxacinLisofylline may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lisofylline is combined with Lornoxicam.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Lisofylline.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Lisofylline.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lisofylline is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Lisofylline.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Magnesium salicylate.Approved
Magnesium sulfateMagnesium sulfate may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Lisofylline.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Lisofylline is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Mefenamic acid.Approved
MelagatranLisofylline may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Lisofylline is combined with Meloxicam.Approved, Vet Approved
MepindololLisofylline may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Lisofylline.Approved, Investigational, Withdrawn
MethimazoleThe serum concentration of Lisofylline can be increased when it is combined with Methimazole.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Lisofylline.Approved
MethsuximideMethsuximide may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lisofylline.Approved
MetipranololLisofylline may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lisofylline.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Lisofylline.Approved, Investigational
MicronomicinLisofylline may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Lisofylline.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Lisofylline.Approved
MizoribineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Lisofylline.Approved
MoxifloxacinThe metabolism of Lisofylline can be decreased when combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lisofylline.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lisofylline.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Nabumetone.Approved
NadololLisofylline may decrease the antihypertensive activities of Nadolol.Approved
NadroparinLisofylline may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatLisofylline may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lisofylline.Approved
Nalidixic AcidLisofylline may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Lisofylline is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Lisofylline is combined with NCX 1022.Investigational
NeamineLisofylline may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololLisofylline may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinLisofylline may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Nepafenac.Approved, Investigational
NetilmicinLisofylline may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Niflumic Acid.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Nitroaspirin.Investigational
NorfloxacinLisofylline may increase the neuroexcitatory activities of Norfloxacin.Approved
NylidrinThe risk or severity of adverse effects can be increased when Nylidrin is combined with Lisofylline.Approved
NystatinThe metabolism of Lisofylline can be decreased when combined with Nystatin.Approved, Vet Approved
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Lisofylline.Approved, Investigational
OfloxacinLisofylline may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lisofylline.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lisofylline.Approved
OlsalazineLisofylline may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Lisofylline is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Lisofylline is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Lisofylline.Vet Approved
OtamixabanLisofylline may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Oxaprozin.Approved
Oxolinic acidLisofylline may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololLisofylline may decrease the antihypertensive activities of Oxprenolol.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Lisofylline.Approved, Investigational
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lisofylline.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Lisofylline is combined with Parecoxib.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Parthenolide.Approved, Investigational
PazufloxacinLisofylline may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinLisofylline may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololLisofylline may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateLisofylline may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateLisofylline may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Perindopril.Approved
PhenindioneLisofylline may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Lisofylline can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenprocoumonLisofylline may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Phenylbutazone.Approved, Vet Approved
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Lisofylline.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lisofylline.Approved, Investigational
PindololLisofylline may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidLisofylline may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Lisofylline.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Lisofylline.Approved, Investigational
Piromidic acidLisofylline may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Lisofylline is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorLisofylline may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinLisofylline may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Lisofylline.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pomalidomide.Approved
Potassium CitrateLisofylline may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololLisofylline may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Lisofylline.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prednicarbate.Approved, Investigational
PrednisoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prednisone.Approved, Vet Approved
PregabalinPregabalin may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Illicit, Investigational
PregnenoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Lisofylline can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Lisofylline.Approved, Investigational
PropafenoneThe serum concentration of Lisofylline can be increased when it is combined with Propafenone.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Lisofylline.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Lisofylline.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Lisofylline.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Lisofylline.Vet Approved
Protein CLisofylline may increase the anticoagulant activities of Protein C.Approved
Protein S humanLisofylline may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeLisofylline may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinLisofylline may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Lisofylline.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Lisofylline.Investigational
PuromycinLisofylline may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Lisofylline.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Lisofylline is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Lisofylline.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinLisofylline may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinLisofylline may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifampicinThe metabolism of Lisofylline can be increased when combined with Rifampicin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Rimexolone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Lisofylline is combined with Rindopepimut.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Risedronate.Approved, Investigational
RivaroxabanLisofylline may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Lisofylline is combined with Rofecoxib.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Lisofylline.Approved
RosoxacinLisofylline may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Rubella virus vaccine.Approved, Investigational
RufloxacinLisofylline may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Lisofylline.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Lisofylline.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lisofylline.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Lisofylline.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Lisofylline.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Lisofylline is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Lisofylline.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Lisofylline.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Lisofylline is combined with Serrapeptase.Investigational
SisomicinLisofylline may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinLisofylline may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SotalolLisofylline may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinLisofylline may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Spirapril.Approved
SRP 299The risk or severity of adverse effects can be increased when Lisofylline is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Lisofylline.Investigational
StreptomycinLisofylline may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulodexideLisofylline may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Lisofylline.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Suxibuzone.Experimental
TacrolimusTacrolimus may increase the immunosuppressive activities of Lisofylline.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Lisofylline.Approved
TalinololLisofylline may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Lisofylline.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Lisofylline.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Lisofylline.Approved
TecemotideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tecemotide.Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lisofylline.Approved, Investigational
TemafloxacinLisofylline may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Lisofylline.Vet Approved
TerbutalineLisofylline may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Lisofylline.Approved
TertatololLisofylline may decrease the antihypertensive activities of Tertatolol.Experimental
TG4010The risk or severity of adverse effects can be increased when Lisofylline is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololLisofylline may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tixocortol.Approved, Withdrawn
TobramycinLisofylline may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibLisofylline may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tolmetin.Approved
TopiramateTopiramate may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Lisofylline.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Trandolapril.Approved
TrastuzumabTrastuzumab may increase the neutropenic activities of Lisofylline.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lisofylline.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lisofylline.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Triamcinolone.Approved, Vet Approved
TriamtereneLisofylline may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Lisofylline.Approved, Vet Approved
TrimethadioneTrimethadione may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Lisofylline.Investigational
TrovafloxacinLisofylline may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinLisofylline may increase the anticoagulant activities of Troxerutin.Investigational
Typhoid VaccineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Typhoid Vaccine.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Lisofylline.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Lisofylline is combined with Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidValproic Acid may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Lisofylline.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Lisofylline is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VinpocetineVinpocetine may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
WarfarinLisofylline may increase the anticoagulant activities of Warfarin.Approved
XimelagatranLisofylline may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Yellow Fever Vaccine.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lisofylline.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Lisofylline.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lisofylline.Withdrawn
ZonisamideZonisamide may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
501254
PubChem Substance
347828652
ChemSpider
438549
ChEMBL
CHEMBL1411
Wikipedia
Lisofylline

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedNot AvailableDiabetes, Diabetes Mellitus Type 1 / Healthy Volunteers1
1, 2TerminatedBasic ScienceDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility7.76 mg/mLALOGPS
logP0.78ALOGPS
logP0.2ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)17.68ChemAxon
pKa (Strongest Basic)-0.85ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area78.67 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity74.65 m3·mol-1ChemAxon
Polarizability30.03 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyrimidines
Sub Class
Purines and purine derivatives
Direct Parent
Xanthines
Alternative Parents
6-oxopurines / Alkaloids and derivatives / Pyrimidones / N-substituted imidazoles / Vinylogous amides / Heteroaromatic compounds / Ureas / Secondary alcohols / Lactams / Azacyclic compounds
show 4 more
Substituents
Xanthine / 6-oxopurine / Purinone / Alkaloid or derivatives / Pyrimidone / N-substituted imidazole / Pyrimidine / Azole / Imidazole / Heteroaromatic compound
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Lee SH, Slattery JT: Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Drug Metab Dispos. 1997 Dec;25(12):1354-8. [PubMed:9394024]

Drug created on October 20, 2016 16:16 / Updated on August 11, 2018 17:00